

Bladder Cancer Update & Renal Cell Cancer Update, 2017

(Video Program)

CME INFORMATION

TARGET AUDIENCE

This activity is intended for medical oncologists, hematologists, hematology-oncology fellows, radiation oncologists, urologists and other healthcare providers involved in the treatment of bladder and renal cell cancers.

OVERVIEW OF ACTIVITY

Cancers of the genitourinary (GU) system affect hundreds of thousands of individuals within the United States each year. Among these, tumors of the bladder, kidney and renal pelvis are among the most prevalent and are therefore the topic of extensive ongoing clinical research. As such, the clinical management of these diseases is currently in a state of evolution, necessitating rapid and consistent access to learning opportunities for clinicians who provide care for these patients. Featuring information on the latest research developments along with expert perspectives, this CME program is designed to assist medical oncologists, urologists and radiation oncologists with the formulation of up-to-date clinical management strategies for the care of patients with GU cancers.

LEARNING OBJECTIVES

- Develop an evidence-based approach to the sequencing of systemic therapies for patients with advanced renal cell carcinoma (RCC), incorporating cytokines, multikinase inhibitors, anti-VEGF antibodies, mTOR inhibitors and immune checkpoint inhibitors.
- Appreciate the recent FDA approvals in advanced RCC, and develop strategies to optimally integrate these agents into the management of this disease.
- Recognize toxicities attributable to diverse molecular-targeted treatments for RCC, and offer preventive or emergent interventions to minimize or ameliorate these side effects.
- Recall the unique mechanism of action of, available clinical trial data with and clinical indications for the use of atezolizumab in patients with relapsed/refractory advanced urothelial bladder cancer, and use this information to guide off-protocol treatment planning.
- Recognize immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutics in order to offer supportive management strategies.

- Recall available and emerging data with novel anti-PD-1/PD-L1 antibodies currently under investigation for bladder cancer and RCC, and, where applicable, refer eligible patients for trial participation or expanded access programs.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Research To Practice designates this enduring material for a maximum of 2 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)

Successful completion of this CME activity enables the participant to earn up to 2 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialty: **medical oncology**.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at [ResearchToPractice.com/Privacy-Policy](https://www.researchtopractice.com/Privacy-Policy) for more information.

HOW TO USE THIS CME ACTIVITY

This CME activity consists of a video component. To receive credit, the participant should watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at [ResearchToPractice.com/RenalBladder117/Video/CME](https://www.researchtopractice.com/RenalBladder117/Video/CME).

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Matthew D Galsky, MD

Director, Genitourinary Medical Oncology
Director, Novel Therapeutics Program
Tisch Cancer Institute
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Advisory Committee: Astellas Pharma Global Development Inc, Genentech BioOncology, Novartis; **Contracted Research:** Bristol-Myers Squibb Company, Celgene Corporation;
Ownership Interest: Dual Therapeutics.

Elizabeth R Plimack, MD, MS

Director, Genitourinary Clinical Research
Associate Professor
Department of Hematology/Oncology
Fox Chase Cancer Center
Temple Health
Philadelphia, Pennsylvania

Advisory Committee: Acceleron Pharma, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis, Pfizer Inc, Roche Laboratories Inc; **Consulting Agreements:** Bristol-Myers Squibb Company, Lilly, Pfizer Inc; **Contracted Research:** Acceleron Pharma, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, GlaxoSmithKline, Lilly, Merck, Pfizer Inc.

Robert J Motzer, MD

Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, New York

Consulting Agreements: Eisai Inc, GlaxoSmithKline, Novartis, Pfizer Inc; **Contracted Research:** Bristol-Myers Squibb Company, Eisai Inc, Genentech BioOncology, Novartis, Pfizer Inc, Roche Laboratories Inc.

Brian I Rini, MD

Department of Solid Tumor Oncology and Urology
Cleveland Clinic Taussig Cancer Center
Associate Professor of Medicine
CCF/CWRU Lerner College of Medicine
Cleveland, Ohio

Consulting Agreements: Merck, Pfizer Inc; **Contracted Research:** Bristol-Myers Squibb Company, Genentech BioOncology, Merck, Pfizer Inc, Roche Laboratories Inc.

EDITOR — **Dr Love** is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

RESEARCH TO PRACTICE STAFF AND EXTERNAL

REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Exelixis Inc, Genentech BioOncology and Novartis.

Hardware/Software Requirements:

A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: May 2017

Expiration date: May 2018

SELECT PUBLICATIONS

Bladder Cancer

- Apolo AB et al. **Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma from the JAVELIN solid tumor phase 1b trial: Analysis of safety, clinical activity, and PD-L1 expression.** *Proc ASCO 2016*;Abstract 4514.
- Balar AV et al. **Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single-arm, multicentre, phase 2 trial.** *Lancet 2017*;389(10064):67-76.
- Balar AV et al. **Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.** *Proc ASCO 2016*;Abstract LBA4500.
- Balar AV et al. **Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study.** *Proc ESMO 2016*;Abstract LBA32_PR.
- Bellmunt J et al. **KEYNOTE-045: Randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer.** *Proc ASCO 2015*;Abstract TPS4571.
- Galsky MD et al. **Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.** *Ann Oncol 2012*;23(2):406-10.
- Massard C et al. **Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.** *Proc ASCO 2016*;Abstract 4502.
- Rosenberg JE et al. **Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial.** *Lancet 2016*;387(10031):1909-20.
- Sharma P et al. **Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer (mUC): Results from the phase I/II CheckMate 032 study.** *Proc ASCO 2016*;Abstract 4501.

Renal Cell Carcinoma

- A phase II, randomized study of atezolizumab (anti PD-L1 antibody) administered as monotherapy or in combination with bevacizumab versus sunitinib in participants with untreated advanced renal cell carcinoma.** NCT01984242
- A phase III, open-label, randomized study of atezolizumab (anti-PD-L1 antibody) in combination with bevacizumab versus sunitinib in patients with untreated advanced renal cell carcinoma.** NCT02420821
- Atkins MB et al. **Axitinib in combination with pembrolizumab in patients (pts) with advanced renal cell carcinoma (aRCC): Preliminary safety and efficacy results.** *Proc ESMO 2016*;Abstract 773PD.
- Choueri T et al. **Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: The Alliance A031203 CABOSUN trial.** *J Clin Oncol 2017*;35(6):591-7.
- Choueri T et al. **Cabozantinib versus everolimus in advanced renal-cell carcinoma.** *N Engl J Med 2015*;373(19):1814-23.
- Haas NB et al. **Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.** *Proc ASCO 2015*;Abstract 403.
- Hammers HJ et al. **Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study.** *Proc ESMO 2016*;Abstract 1062P.
- Hammers HJ et al. **CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.** *Proc ASCO 2015*;Abstract TPS578.
- McDermott DF et al. **Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.** *Proc ASCO 2016*;Abstract 4507.
- Motzer RJ et al. **Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: A randomised, phase 2, open-label, multicentre trial.** *Lancet Oncol 2015*;16(15):1473-82.
- Motzer RJ et al. **Nivolumab versus everolimus in advanced renal-cell carcinoma.** *N Engl J Med 2015*;373(19):1803-13.
- Motzer RJ et al. **Pazopanib versus sunitinib in metastatic renal-cell carcinoma.** *N Engl J Med 2013*;369(8):722-31.
- Ravaud A et al. **Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy.** *N Engl J Med 2016*;375(23):2246-54.